KRYS

For questions about this article or underlying research, email [email protected].

Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Krystal Biotech reports promising early results for KB113, with tumor regression seen in more than 80% of assessed lesions in an early Gorlin syndrome study.

Krystal Biotech, Inc. (NASDAQ:KRYS) reported preliminary clinical findings from a pilot study of KB113, an investigational intratumoral immunotherapy being developed for patients with Gorlin syndrome, showing regression in more than 80% of assessed basal cell…

Krystal Biotech’s VYJUVEK gene therapy for dystrophic epidermolysis bullosa has already delivered strong commercial traction, generating high revenue and robust gross margins in chronic use.

Krystal Biotech (KRYS) is drawing fresh attention after news that its VYJUVEK gene therapy for dystrophic epidermolysis bullosa has gained commercial traction, supported by high revenue, strong gross margins, and recurring treatment demand.

Krystal Biotech has produced a very large 5 year share price gain, which naturally puts the focus on whether that move is supported by the business it has built.

Krystal Biotech, Inc. (NASDAQ:KRYS) has something most biotech companies spend years trying to achieve: a drug that works, is approved, and is already generating meaningful revenue.

KRYS' Vyjuvek growth and expanding genetic medicine pipeline boost investor confidence as the company advances toward multi-product growth.